The National Center for Health Research recommends the FDA postpone approval of the Organ Care System (OCS) Lung due to significant flaws in the INSPIRE trial, including design and implementation issues. These compromise the reliability of its findings and pose risks to patient safety.
Read More »On Medical Treatments & Products
NCHR Comment on the USPSTF’s Draft Recommendations for Breast Cancer: Medications for Risk Reduction
April 19, 2017. We support the USPSTF’s efforts to re-evaluate recommendations as the scientific evidence expands and improves. In addition, we strongly urge the USPSTF to consider how the apparently modest benefits of medications compare to specific lifestyle changes for reducing breast cancer risk.
Read More »NCHR Comment on the USPSTF’s Draft Recommendations for BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing
April 12, 2017. We support the USPSTF’s efforts to provide updated recommendations on risk assessment, genetic counseling, and genetic testing on BRCA-related cancer, based on quality, up-to-date scientific studies. We hope the review will quantify the benefits and harms of each step starting with screening, in order to help USPSTF to make meaningful recommendations for appropriate subpopulations of women.
Read More »NCHR Testimony at FDA on Opioid, Opana ER
March 14, 2017. Compared with other opioids, reformulated Opana ER, along with its generic counterpart, had the highest injection abuse rates following reformulation.
Read More »NCHR Testimony at FDA Meeting about Abuse-Deterrent Opioid, Roxybond
April 5, 2017. Dr. Megan Polanin testifies at the FDA, stating that there is still abuse potential for the intranasal and intravenous use of RoxyBond in the midst of the nation’s opoiod epidemic.
Read More »